Amber Therapeutics
Aidan Crawley is the Co-Founder and CEO of Amber Therapeutics, a company focused on developing bioelectrical therapies for patients with peripheral nervous system disorders. Before their current role, Aidan was a Founder of Utter, a company addressing mental health issues related to emotional isolation. Aidan also held various positions in companies such as Masomo, Addepar, and Goldman Sachs, and has a background in financial analysis and business development. Aidan's educational background includes a BA in English Literature from Brasenose College, Oxford.
This person is not in any teams
Amber Therapeutics
Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt and respond to a patient’s individual signals thereby restoring normal physiological function. Amber Therapeutics was founded by a multidisciplinary team of clinicians, translational neuroengineers, medtech industry professionals and experienced entrepreneurs focused on developing transformational therapy innovation for major unmet medical conditions. The Company is backed by Oxford Science Enterprises and 8VC.